
NRIX Valuation
Nurix Therapeutics Inc
- Overview
- Forecast
- Valuation
- Earnings
NRIX Relative Valuation
NRIX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NRIX is overvalued; if below, it's undervalued.
Historical Valuation
Nurix Therapeutics Inc (NRIX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 11.87 is considered Undervalued compared with the five-year average of -6.63. The fair price of Nurix Therapeutics Inc (NRIX) is between 22.54 to 38.62 according to relative valuation methord. Compared to the current price of 9.41 USD , Nurix Therapeutics Inc is Undervalued By 58.25%.
Relative Value
Fair Zone
22.54-38.62
Current Price:9.41
58.25%
Undervalued
-2.65
PE
1Y
3Y
5Y
Trailing
Forward
-1.07
EV/EBITDA
Nurix Therapeutics Inc. (NRIX) has a current EV/EBITDA of -1.07. The 5-year average EV/EBITDA is -4.41. The thresholds are as follows: Strongly Undervalued below -13.18, Undervalued between -13.18 and -8.79, Fairly Valued between -0.02 and -8.79, Overvalued between -0.02 and 4.36, and Strongly Overvalued above 4.36. The current Forward EV/EBITDA of -1.07 falls within the Historic Trend Line -Fairly Valued range.
-0.89
EV/EBIT
Nurix Therapeutics Inc. (NRIX) has a current EV/EBIT of -0.89. The 5-year average EV/EBIT is -3.99. The thresholds are as follows: Strongly Undervalued below -11.51, Undervalued between -11.51 and -7.75, Fairly Valued between -0.22 and -7.75, Overvalued between -0.22 and 3.54, and Strongly Overvalued above 3.54. The current Forward EV/EBIT of -0.89 falls within the Historic Trend Line -Fairly Valued range.
11.70
PS
Nurix Therapeutics Inc. (NRIX) has a current PS of 11.70. The 5-year average PS is 19.39. The thresholds are as follows: Strongly Undervalued below -5.97, Undervalued between -5.97 and 6.71, Fairly Valued between 32.07 and 6.71, Overvalued between 32.07 and 44.75, and Strongly Overvalued above 44.75. The current Forward PS of 11.70 falls within the Historic Trend Line -Fairly Valued range.
-3.22
P/OCF
Nurix Therapeutics Inc. (NRIX) has a current P/OCF of -3.22. The 5-year average P/OCF is -8.45. The thresholds are as follows: Strongly Undervalued below -24.51, Undervalued between -24.51 and -16.48, Fairly Valued between -0.42 and -16.48, Overvalued between -0.42 and 7.61, and Strongly Overvalued above 7.61. The current Forward P/OCF of -3.22 falls within the Historic Trend Line -Fairly Valued range.
-2.86
P/FCF
Nurix Therapeutics Inc. (NRIX) has a current P/FCF of -2.86. The 5-year average P/FCF is -6.73. The thresholds are as follows: Strongly Undervalued below -17.37, Undervalued between -17.37 and -12.05, Fairly Valued between -1.42 and -12.05, Overvalued between -1.42 and 3.90, and Strongly Overvalued above 3.90. The current Forward P/FCF of -2.86 falls within the Historic Trend Line -Fairly Valued range.
Nurix Therapeutics Inc (NRIX) has a current Price-to-Book (P/B) ratio of 1.61. Compared to its 3-year average P/B ratio of 2.44 , the current P/B ratio is approximately -34.11% higher. Relative to its 5-year average P/B ratio of 2.87, the current P/B ratio is about -43.93% higher. Nurix Therapeutics Inc (NRIX) has a Forward Free Cash Flow (FCF) yield of approximately -30.93%. Compared to its 3-year average FCF yield of -24.14%, the current FCF yield is approximately 28.13% lower. Relative to its 5-year average FCF yield of -17.96% , the current FCF yield is about 72.15% lower.
1.61
P/B
Median3y
2.44
Median5y
2.87
-31.39
FCF Yield
Median3y
-24.14
Median5y
-17.96
Competitors Valuation Multiple
The average P/S ratio for NRIX's competitors is 100.85, providing a benchmark for relative valuation. Nurix Therapeutics Inc Corp (NRIX) exhibits a P/S ratio of 11.70, which is -88.40% above the industry average. Given its robust revenue growth of 264.34%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of NRIX decreased by 62.66% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 12.09M to 44.06M.
The secondary factor is the Margin Expansion, contributed -73.22%to the performance.
Overall, the performance of NRIX in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch

COUR
Coursera Inc
11.500
USD
-0.95%

SGML
Sigma Lithium Corp
6.710
USD
+3.39%

MDXG
MiMedx Group Inc
7.100
USD
-1.11%

USPH
US Physical Therapy Inc
82.890
USD
+0.16%

KNSA
Kiniksa Pharmaceuticals International PLC
33.490
USD
-0.03%

AMPL
Amplitude Inc
11.430
USD
-2.47%

XNCR
Xencor Inc
8.130
USD
+0.99%

OXM
Oxford Industries Inc
44.050
USD
-1.74%

AMC
AMC Entertainment Holdings Inc
2.810
USD
-0.71%

TV
Grupo Televisa SAB
2.790
USD
+0.72%
FAQ

Is Nurix Therapeutics Inc (NRIX) currently overvalued or undervalued?
Nurix Therapeutics Inc (NRIX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 11.87 is considered Undervalued compared with the five-year average of -6.63. The fair price of Nurix Therapeutics Inc (NRIX) is between 22.54 to 38.62 according to relative valuation methord. Compared to the current price of 9.41 USD , Nurix Therapeutics Inc is Undervalued By 58.25% .

What is Nurix Therapeutics Inc (NRIX) fair value?

How does NRIX's valuation metrics compare to the industry average?

What is the current P/B ratio for Nurix Therapeutics Inc (NRIX) as of Aug 29 2025?

What is the current FCF Yield for Nurix Therapeutics Inc (NRIX) as of Aug 29 2025?

What is the current Forward P/E ratio for Nurix Therapeutics Inc (NRIX) as of Aug 29 2025?
